cytosine has been researched along with gemcitabine in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (9.52) | 18.2507 |
| 2000's | 14 (66.67) | 29.6817 |
| 2010's | 5 (23.81) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Deeter, JB; Hausheer, FH; Hertel, LW; Jones, ND; Kroin, JS; Seetharamulu, P; Singh, UC | 1 |
| Robins, MJ; Samano, V; Silva, DJ; Stubbe, J | 1 |
| Jolivet, J; Locas, C; Marty, J; Von Hoff, DD; Weitman, S | 1 |
| Dumontet, C; Galmarini, CM; Mackey, JR | 1 |
| Günzburg, WH; Salmons, B | 1 |
| Johnson, SA | 1 |
| Cass, CE; Clarke, ML; Gourdeau, H; Jolivet, J; Lafrenière, RG; Lee, N; Mackey, JR; Mowles, D; Ouellet, F; Richard, A; Selner, M; Young, JD | 1 |
| Bernacki, RJ; Chaudhary, ND; Greco, W; Hoffman, RM; Kobayashi, T; Mazurchuk, R; Pera, P; Spernyak, J; Veith, J; Wu, M | 1 |
| Cortes, J; Giles, F; Kantarjian, H; Ravandi, F | 1 |
| Cheng, YC; Lam, W; Leung, CH; Park, SY | 1 |
| Adema, AD; Albertoni, F; Floor, K; Hubeek, I; Kaspers, GJ; Peters, GJ; Zuurbier, L | 1 |
| Bussom, S; Cheng, YC; Lam, W; Leung, CH | 1 |
| Bouffard, DY; Cass, CE; Clarke, ML; Damaraju, VL; Gourdeau, H; Grey, M; Leblond, L; Mackey, JR; Wong, CK | 1 |
| Benhadji, K; Calvo, F; Chiao, J; Cvitkovic, E; Faivre, S; Galmarini, CM; Ghoul, A; Green, SR; Le Tourneau, C; Raymond, E; Serova, M | 1 |
| Campbell, DO; Czernin, J; Herschman, HR; Laing, RE; Phelps, ME; Radu, CG; Satyamurthy, N; Walter, MA; Witte, ON | 1 |
| Bussom, S; Cheng, YC; Lam, W | 1 |
| André, N; Ciccolini, J; Dahan, L; Mercier, C; Ouafik, L | 1 |
| Campbell, DO; Czernin, J; Lee, JT; Radu, CG; Satyamurthy, N | 1 |
| Diaz, I; Muggia, F; Peters, GJ | 1 |
| Liu, XJ; Nowak, B; Plunkett, W; Wang, YQ | 1 |
| Desai, P; Haimovitz-Friedman, A; Humm, JL; Kramer, RM; Lowery, MA; Pillarsetty, N; Romesser, PB; Russell, J | 1 |
4 review(s) available for cytosine and gemcitabine
| Article | Year |
|---|---|
Nucleoside analogues: mechanisms of drug resistance and reversal strategies.
Topics: 2-Chloroadenosine; 5'-Nucleotidase; Acute Disease; Animals; Antimetabolites, Antineoplastic; Arabinonucleosides; Biological Transport; Carrier Proteins; Cytarabine; Cytidine Deaminase; Cytosine; Deoxyadenosines; Deoxycytidine; Deoxycytidine Kinase; Dioxolanes; DNA Repair; DNA Replication; DNA-Directed DNA Polymerase; Drug Resistance, Neoplasm; Gemcitabine; Hematopoietic Cell Growth Factors; Humans; Leukemia, Myeloid; Lymphoproliferative Disorders; Neoplastic Stem Cells; Nucleosides; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Remission Induction; Ribonucleotide Reductases; Vidarabine | 2001 |
Novel clinical strategies for the treatment of pancreatic carcinoma.
Topics: Adjuvants, Immunologic; Antibodies, Monoclonal; Antineoplastic Agents; Bile; Biotransformation; Cancer Vaccines; Carcinoma; Clinical Trials as Topic; Cytochrome P-450 CYP2B1; Cytosine; Deoxycytidine; Dioxolanes; DNA, Antisense; Endopeptidases; Enzyme Inhibitors; Gemcitabine; Genes, p53; Genes, ras; Genetic Therapy; Heat-Shock Proteins; Humans; Ifosfamide; Multicenter Studies as Topic; Neoplasm Proteins; Neoplastic Stem Cells; Pancreatic Neoplasms; Pectins; Pilot Projects; Polyamines; Prospective Studies; Prostheses and Implants; Sesquiterpenes; Spiro Compounds; Tissue Extracts; Topoisomerase I Inhibitors | 2001 |
Nucleoside analogues in the treatment of haematological malignancies.
Topics: Antimetabolites, Antineoplastic; Arabinonucleosides; Biological Transport; Cladribine; Clinical Trials as Topic; Cytarabine; Cytosine; Deoxycytidine; Dioxolanes; Economics, Pharmaceutical; Gemcitabine; Guidelines as Topic; Hematologic Neoplasms; Humans; Molecular Structure; Nucleosides; Pentostatin; Vidarabine | 2001 |
New agents in acute myeloid leukemia and other myeloid disorders.
Topics: Antineoplastic Agents; Cyclosporine; Cytosine; Deoxycytidine; Dioxolanes; Female; Gemcitabine; Humans; Immunosuppressive Agents; Immunotherapy; Leukemia, Myeloid, Acute; Male; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Severity of Illness Index; Survival Analysis; Treatment Outcome | 2004 |
17 other study(ies) available for cytosine and gemcitabine
| Article | Year |
|---|---|
Ab initio quantum mechanical and X-ray crystallographic studies of gemcitabine and 2'-deoxy cytosine.
Topics: Antimetabolites, Antineoplastic; Chemical Phenomena; Chemistry, Physical; Crystallography, X-Ray; Cytosine; Deoxycytidine; Gemcitabine; Models, Molecular | 1996 |
Gemcitabine 5'-triphosphate is a stoichiometric mechanism-based inhibitor of Lactobacillus leichmannii ribonucleoside triphosphate reductase: evidence for thiyl radical-mediated nucleotide radical formation.
Topics: Cytosine; Deoxyadenosines; Deoxycytidine; Electron Spin Resonance Spectroscopy; Enzyme Activation; Enzyme Inhibitors; Enzyme Stability; Fluorides; Free Radicals; Gemcitabine; Lactobacillus; Peptides; Protein Denaturation; Ribonucleotide Reductases; Spectrophotometry, Ultraviolet; Sulfhydryl Compounds; Vitamin B 12 | 1998 |
The new dioxolane, (-)-2'-deoxy-3'-oxacytidine (BCH-4556, troxacitabine), has activity against pancreatic human tumor xenografts.
Topics: Animals; Antineoplastic Agents; Body Weight; Cytosine; Deoxycytidine; Dioxolanes; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Pancreatic Neoplasms; Transplantation, Heterologous; Tumor Cells, Cultured | 2000 |
Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines.
Topics: Amino Acid Sequence; Antineoplastic Agents; Biological Transport; Carrier Proteins; Cytarabine; Cytidine Deaminase; Cytosine; Deoxycytidine; Deoxycytidine Kinase; Dioxolanes; Drug Resistance, Neoplasm; Gemcitabine; Humans; Leukemia; Male; Membrane Proteins; Molecular Sequence Data; Nucleoside Transport Proteins; Phosphorylation; Prostatic Neoplasms; Sequence Homology, Amino Acid; Sodium; Stereoisomerism; Tritium; Tumor Cells, Cultured; Uridine | 2001 |
High-resolution magnetic resonance imaging of the efficacy of the cytosine analogue 1-[2-C-cyano-2-deoxy-beta-D-arabino-pentofuranosyl]-N(4)-palmitoyl cytosine (CS-682) in a liver-metastasis athymic nude mouse model.
Topics: Animals; Antineoplastic Agents; Arabinonucleosides; Cell Division; Colonic Neoplasms; Cytosine; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Mice; Mice, Nude; Xenograft Model Antitumor Assays | 2003 |
Apurinic/apyrimidinic endonuclease-1 protein level is associated with the cytotoxicity of L-configuration deoxycytidine analogs (troxacitabine and beta-L-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine) but not D-configuration deoxycytidine analogs (gemcit
Topics: Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Cytosine; Deoxycytidine; Dioxolanes; DNA-(Apurinic or Apyrimidinic Site) Lyase; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; RNA, Small Interfering; Transfection | 2006 |
Cellular resistance against troxacitabine in human cell lines and pediatric patient acute myeloid leukemia blast cells.
Topics: Antineoplastic Agents; Catalysis; Cell Line, Tumor; Cladribine; Cytosine; Deoxycytidine; Dioxolanes; Drug Resistance, Neoplasm; Gemcitabine; HeLa Cells; HL-60 Cells; Humans; Inhibitory Concentration 50; Leukemia, Myeloid, Acute; Models, Chemical; Nucleosides | 2006 |
The impact of hypoxic treatment on the expression of phosphoglycerate kinase and the cytotoxicity of troxacitabine and gemcitabine.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma; Carcinoma, Hepatocellular; Cell Hypoxia; Cell Line, Tumor; Colonic Neoplasms; Cytosine; Deoxycytidine; Dioxolanes; DNA-(Apurinic or Apyrimidinic Site) Lyase; Gemcitabine; Humans; Liver Neoplasms; Pancreatic Neoplasms; Phosphoglycerate Kinase; Rhabdomyosarcoma | 2007 |
Synergistic activity of troxacitabine (Troxatyl) and gemcitabine in pancreatic cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Cytosine; Deoxycytidine; Dioxolanes; Drug Synergism; Female; Gemcitabine; Humans; Mice; Mice, Nude; Mice, SCID; Pancreatic Neoplasms; Treatment Outcome; Tritium; Tumor Cells, Cultured; Uridine; Xenograft Model Antitumor Assays | 2007 |
Antiproliferative effects of sapacitabine (CYC682), a novel 2'-deoxycytidine-derivative, in human cancer cells.
Topics: 5'-Nucleotidase; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Cytarabine; Cytosine; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Equilibrative Nucleoside Transporter 1; Gemcitabine; Gene Expression Regulation, Neoplastic; HCT116 Cells; HT29 Cells; Humans; Inhibitory Concentration 50; Molecular Structure; Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Taxoids | 2007 |
Noninvasive prediction of tumor responses to gemcitabine using positron emission tomography.
Topics: Animals; Antineoplastic Agents; Cytosine; Deoxycytidine; Gemcitabine; Humans; Leukemia; Mice; Positron-Emission Tomography | 2009 |
Effect of hypoxia on the expression of phosphoglycerate kinase and antitumor activity of troxacitabine and gemcitabine in non-small cell lung carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Death; Cell Hypoxia; Cell Line, Tumor; Cytosine; Deoxycytidine; Dioxolanes; Dose-Response Relationship, Drug; Gemcitabine; Hemodynamics; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Neoplasm Proteins; Phosphoglycerate Kinase; Response Elements; Transcription, Genetic; Xenograft Model Antitumor Assays | 2009 |
Letter to the editor: pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism.
Topics: Adenine; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Confounding Factors, Epidemiologic; Cytidine Deaminase; Cytosine; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Research Design | 2010 |
Stratification of nucleoside analog chemotherapy using 1-(2'-deoxy-2'-18F-fluoro-β-D-arabinofuranosyl)cytosine and 1-(2'-deoxy-2'-18F-fluoro-β-L-arabinofuranosyl)-5-methylcytosine PET.
Topics: Adenine Nucleotides; Animals; Arabinonucleosides; Cell Line, Tumor; Clofarabine; Cytarabine; Cytidine Deaminase; Cytosine; Deoxycytidine; Deoxycytidine Kinase; Fluorine Radioisotopes; Gemcitabine; Gene Expression Regulation, Neoplastic; Leukemia, Lymphoid; Mice; Positron-Emission Tomography; Treatment Outcome | 2012 |
Nucleoside and nucleobase analogs in cancer treatment: not only sapacitabine, but also gemcitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Arabinonucleosides; Cytosine; Deoxycytidine; Gemcitabine; Humans; Neoplasms; Nucleosides | 2012 |
Sapacitabine, the prodrug of CNDAC, is a nucleoside analog with a unique action mechanism of inducing DNA strand breaks.
Topics: Animals; Antimetabolites, Antineoplastic; Arabinonucleosides; CHO Cells; Cricetinae; Cricetulus; Cytarabine; Cytosine; Deoxycytidine; DNA Breaks, Double-Stranded; DNA Repair; DNA-Binding Proteins; Gemcitabine; Homologous Recombination; Inhibitory Concentration 50; Prodrugs | 2012 |
In Vitro and In Vivo Comparison of Gemcitabine and the Gemcitabine Analog 1-(2'-deoxy-2'-fluoroarabinofuranosyl) Cytosine (FAC) in Human Orthotopic and Genetically Modified Mouse Pancreatic Cancer Models.
Topics: Animals; Cell Line, Tumor; Cytosine; Deoxycytidine; Female; Gemcitabine; Humans; Mice, Nude; Mice, Transgenic; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2017 |